KRAS and acute myeloid leukemia: FBL, as part of the snoRNP complex with NOP56, NOP58, and NHP2L1 (15.5K), is overexpressed in AML, where high NOP56 levels delay remission [40], while NOP56 downregulation inhibits the proliferation of KRAS-mutant (G13D) CRC cells DLD1 and HCT116 [41].